Raising Funds for Healthcare Business Investment Through Convertible Bonds
First written in FY2017-Q2. 2 of 4 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2020.
20 other companies' latest entry also says "Achieved".
- FY2020AchievedAnnual report
「Decrease due to the extinguishment of stock acquisition rights upon maturity redemption of the 2nd Series of Unsecured Convertible Bonds with Stock Acquisition Rights: 1,537,528 shares」
The 2nd Series of Convertible Bonds with Stock Acquisition Rights, which had been a means of raising funds for healthcare investment, was redeemed at maturity, resulting in the extinguishment of stock acquisition rights for 1,537,528 shares. - FY2017AdvancedAnnual report
「In the healthcare field, we view its large potential market as a pillar of medium-term growth and are actively investing in it. In December 2016, we raised ¥2.5 billion to fund healthcare investments through a third-party allotment of unsecured convertible bonds with stock acquisition rights.」
The company confirmed for the full fiscal year that it had positioned healthcare investment as a pillar of medium-term growth and raised funds through ¥2.5 billion of convertible bonds with stock acquisition rights. - FY2017-Q3AdvancedAnnual report
「The convertible bonds with stock acquisition rights issued during the current third-quarter accounting period were as follows. Number of shares underlying the stock acquisition rights: 3,075,030 shares. Exercise price per share: ¥813.」
The issuance of convertible bonds with stock acquisition rights intended to fund research and development and other activities in the healthcare business progressed, along with the exercise of some stock acquisition rights, making the capital raising more concrete. - FY2017-Q2First statedAnnual report
「Total issue amount ¥2,500 million The funds will be used for research and development related to the healthcare business, system development, establishment of a sales structure, identification of collaboration partners, alliances including capital participation, and M&A. The planned spending period is from December 2016 through November 2021.」
The company decided to issue the 2nd Series of Unsecured Convertible Bonds with Stock Acquisition Rights for a total issue amount of ¥2.5 billion. From December 2016 through November 2021, the funds were planned for use in healthcare research and development, system development, establishment of a sales structure, alliances and M&A, among other purposes.